Copley Financial Group Inc. Sells 822 Shares of Medtronic PLC $MDT

Copley Financial Group Inc. lowered its stake in Medtronic PLC (NYSE:MDT) by 10.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,965 shares of the medical technology company’s stock after selling 822 shares during the quarter. Copley Financial Group Inc.’s holdings in Medtronic were worth $607,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Gilbert & Cook Inc. lifted its position in Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after acquiring an additional 114 shares in the last quarter. Red Spruce Capital LLC raised its stake in shares of Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after purchasing an additional 118 shares during the period. Certior Financial Group LLC lifted its holdings in shares of Medtronic by 3.7% in the first quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after purchasing an additional 122 shares in the last quarter. PrairieView Partners LLC boosted its position in shares of Medtronic by 3.6% during the second quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock worth $324,000 after buying an additional 128 shares during the period. Finally, Baker Avenue Asset Management LP grew its holdings in shares of Medtronic by 3.1% during the first quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company’s stock worth $410,000 after buying an additional 136 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of MDT opened at $105.13 on Thursday. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The company’s fifty day simple moving average is $95.68 and its 200 day simple moving average is $91.39. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33. The company has a market cap of $134.85 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Leerink Partners set a $120.00 target price on Medtronic and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. Wells Fargo & Company increased their target price on shares of Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Stifel Nicolaus raised their target price on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Finally, Morgan Stanley boosted their price target on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $109.72.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.